Abstract: A Yeast Artificial Chromosome (YAC) directing the expression of one or more activities of the humanized glycosylation pathway is provided. The said YAC comprises one or more expression cassettes for fusion proteins of heterologous glycosylation pathway and an ER/Golgi retention sequence. The invention also relates to new yeast cells which contain the said YAC. Finally, the invention also provides a method for producing recombinant target glycoproteins.

Abstract: The present application relates to genetically modified yeasts for the production of glycoproteins having optimized and homogeneous glycan structures. These yeasts comprise an inactivation of the Och 1 gene, the integration by homologous recombination, into an auxotrophic marker, of an expression cassette comprising a first promoter, and an open reading frame comprising the coding sequence for an ?-1,2-mannosidase I, and the integration of a cassette comprising a second promoter different from said first promoter and the coding sequence for an exogenous glycoprotein. These yeasts make it possible to produce EPO with an optimized and 98% homogeneous glycosylation.

Abstract: The invention relates to steps for the development or the quality control of recombinant monoclonal antibodies (MoAbr) used as medicaments, and also to the selection of the patients liable to effectively respond to a treatment with a given monoclonal antibody.

Abstract: The present application relates to genetically modified yeasts for the production of glycoproteins having optimized and homogeneous glycan structures. These yeasts comprise an inactivation of the Och 1 gene, the integration by homologous recombination, into an auxotrophic marker, of an expression cassette comprising a first promoter, and an open reading frame comprising the coding sequence for an ?-1,2-mannosidase I, and the integration of a cassette comprising a second promoter different from said first promoter and the coding sequence for an exogenous glycoprotein. These yeasts make it possible to produce EPO with an optimized and 98% homogeneous glycosylation.